Whitney R. Buckel

Whitney R. Buckel

Auto-generated profile, based on publicly available information

Whitney R. Buckel

Department of Pharmacy, Intermountain Health , Salt Lake City, Utah

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Medical Clinics of North America
Verified
Journal Article
Closed access
WBWhitney R. Buckel
Whitney R. Buckel
JVJohn J. Veillette
John J. Veillette
TVTodd J. Vento
Todd J. Vento
ESEdward Stenehjem
Edward Stenehjem

18 December 2014 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
WBWhitney R. Buckel
Whitney R. Buckel
EAEdina Avdic
Edina Avdic
KCKaren C. Carroll
Karen C. Carroll
VGVidhya Gunaseelan
Vidhya Gunaseelan
EHEric Hadhazy
Eric Hadhazy
SCSara E. Cosgrove
Sara E. Cosgrove
We evaluated the impact of nursing education and stewardship interventions on Clostridium difficile testing and treatment appropriateness. Diarrhea documentation increased for those with positive tests (45% to 70%); pretreatment laxative use decreased (50% to 19%). Appropriate treatment increased for severe infection (57% to 93%), but all asymptomatically colonized patients were treated.Infect Control Hosp Epidemiol 2014;00(0): 1–5

1 April 2021 in Annals of the American Thoracic Society
Verified
Journal Article
Open access
SBSamuel M. Brown
Samuel M. Brown
IPIthan Peltan
Ithan Peltan
NKNaresh Kumar
Naresh Kumar
LLLindsay Leither
Lindsay Leither
BWBrandon J. Webb
Brandon J. Webb
TGTom Greene
Tom Greene
Rationale: The coronavirus disease (COVID-19) pandemic struck an immunologically naive, globally interconnected population. In the face of a new infectious agent causing acute respiratory failure for which there were no known effective therapies, rapid, often pragmatic trials were necessary to evaluate potential treatments, frequently starting with medications that are already marketed for other indications. Early in the pandemic, hydroxychloroquine and azithromycin were two such candidates. Objectives: To assess the relative efficacy of hydroxychloroquine and azithromycin among hospitalized patients with COVID-19. Methods: We performed a randomized clinical trial of hydroxychloroquine versus azithromycin among hospitalized patients with COVID-19. Treatment was 5 days of study medication. The primary endpoint was the COVID ordinal outcomes scale at Day 14. Secondary endpoints included hospital-, intensive care unit–, and ventilator-free days at Day 28. The trial was stopped early after the enrollment of 85 patients when a separate clinical trial concluded that a clinically important effect of hydroxychloroquine over placebo was definitively excluded. Comparisons were made a priori using a proportional odds model from a Bayesian perspective. Results: We enrolled 85 patients at 13 hospitals over 11 weeks. Adherence to study medication was high. The estimated odds ratio for less favorable status on the ordinal scale for hydroxychloroquine versus azithromycin from the primary analysis was 1.07, with a 95% credible interval from 0.63 to 1.83 with a posterior probability of 60% that hydroxychloroquine was worse than azithromycin. Secondary outcomes displayed a similar slight preference for azithromycin over hydroxychloroquine. QTc prolongation was rare and did not differ between groups. The 20 safety outcomes were similar between arms, with the possible exception of postrandomization-onset acute kidney injury, which was more common with hydroxychloroquine (15% vs. 0%). Patients in the hydroxychloroquine arm received remdesivir more often than those in the azithromycin arm (19% vs. 2%). There was no apparent association between remdesivir use and acute kidney injury. Conclusions: Although early termination limits the precision of our results, we found no suggestion of substantial efficacy for hydroxychloroquine over azithromycin. Acute kidney injury may be more common with hydroxychloroquine than azithromycin, although this may be due to the play of chance. Differential use of remdesivir may have biased our results in favor of hydroxychloroquine. Our results are consistent with conclusions from other trials that hydroxychloroquine cannot be recommended for inpatients with COVID-19; azithromycin may merit additional investigation. Clinical trial registered with http://www.clinicaltrials.gov/ (NCT04329832).

8 July 2014 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
VFValeria Fabre
Valeria Fabre
MFMarcela Ferrada
Marcela Ferrada
WBWhitney R. Buckel
Whitney R. Buckel
EAEdina Avdic
Edina Avdic
SCSara E. Cosgrove
Sara E. Cosgrove
No clinical trials have investigated the use of ceftaroline fosamil for salvage therapy of methicillin-resistant Staphylococcus aureus bacteremia and endocarditis. We report data on 29 patients who received ceftaroline ± another antimicrobial for this indication. Ninety percent of patients had microbiologic cure and 31% had treatment success with a median follow-up of 6 months.

27 December 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
SASameer Alzaidi
Sameer Alzaidi
JVJohn J Veillette
John J Veillette
SMStephanie S May
Stephanie S May
JOJared Olson
Jared Olson
KJKatarina Jackson
Katarina Jackson
BWBrandon J Webb
Brandon J Webb
Fluoroquinolones (FQs) are effective for oral step-down therapy for gram-negative bloodstream infections but are associated with unfavorable toxic effects. Robust data are lacking for trimethoprim-sulfamethoxazole (TMP-SMX) and high-bioavailability β-lactams (HBBLs). In this multicenter observational cohort study, we simulated a 3-arm registry trial using causal inference methods to compare the effectiveness of FQs, TMP-SMX, or HBBLs for gram-negative bloodstream infections oral step-down therapy. The study included adults treated between January 2016 and December 2022 for uncomplicated Escherichia coli or Klebsiella species bacteremia of urinary tract origin who were who were transitioned to an oral regimen after ≤4 days of effective intravenous antibiotics. Propensity weighting was used to balance characteristics between groups. 60-day recurrence was compared using a multinomial Cox proportional hazards model with probability of treatment weighting. Of 2571 patients screened, 648 (25%) were included. Their median age (interquartile range) was 67 (45–78) years, and only 103 (16%) were male. Characteristics were well balanced between groups. Compared with FQs, TMP-SMX had similar effectiveness (adjusted hazard ratio, 0.91 [95% confidence interval, .30–2.78]), and HBBLs had a higher risk of recurrence (2.19 [.95–5.01]), although this difference was not statistically significant. Most HBBLs (70%) were not optimally dosed for bacteremia. A total antibiotic duration ≤8 days was associated with a higher recurrence rate in select patients with risk factors for failure. FQs and TMP-SMX had similar effectiveness in this real-world data set. HBBLs were associated with higher recurrence rates but suboptimal dosing may have contributed. Further studies are needed to define optimal BL dosing and duration to mitigate treatment failures. https://tidbitapp.io/tidbits/oral-beta-lactams-fluoroquinolones-or-trimethoprim-sulfamethoxazole-for-definitive-treatment-of-uncomplicated-escherichia-coli-or-klebsiella-species-bacteremia-from-a-urinary-source

1 August 2020 in Annals of the American Thoracic Society
Verified
Journal Article
Open access
SBSamuel M. Brown
Samuel M. Brown
IPIthan D. Peltan
Ithan D. Peltan
BWBrandon Webb
Brandon Webb
NKNaresh Kumar
Naresh Kumar
NSNathan Starr
Nathan Starr
TGTom Greene
Tom Greene
Coronavirus disease (COVID-19) is a potentially fatal illness with no proven therapy beyond excellent supportive care. Treatments are urgently sought. Adaptations to traditional trial logistics and design to allow rapid implementation, evaluation of trials within a global trials context, flexible interim monitoring, and access outside traditional research hospitals (even in settings where formal placebos are unavailable) may be helpful. Thoughtful adaptations to traditional trial designs, especially within the global context of related studies, may also foster collaborative relationships among government, community, and the research enterprise. Here, we describe the protocol for a pragmatic, active comparator trial in as many as 300 patients comparing two current “off-label” treatments for COVID-19—hydroxychloroquine and azithromycin—in academic and nonacademic hospitals in Utah. We developed the trial in response to local pressures for widespread, indiscriminate off-label use of these medications. We used a hybrid Bayesian-frequentist design for interim monitoring to allow rapid, contextual assessment of the available evidence. We also developed an inference grid for interpreting the range of possible results from this trial within the context of parallel trials and prepared for a network meta-analysis of the resulting data. This trial was prospectively registered (ClinicalTrials.gov Identifier: NCT04329832) before enrollment of the first patient. Clinical trial registered with www.clinicaltrials.gov (NCT04329832).